Abstract:
There is provided a fast acting subminiature cylindrical fuse having a cylindrical cover substantially locked onto a cylindrical base. The locking mechanism for the cover comprises a plurality of grooves and a plurality of corresponding projections on the internal surface of the cover and the external surface of the fuse base. The lock projections have a relatively straight diverging upper surface and a rounded bottom locking surface. The fuse base has a spacing ridge on the bottom thereof that spaces the fuse bottom surface above a circuit board surface. The fuse also has a plurality of pressure relieving passageways extending from inside the fuse to the outside of the fuse.
Abstract:
A method for screening bacteria to select strains which will suppress Pythium spp. in small grain crops under field conditions and a method for applying field-suppressive bacteria to suppress Pythium spp. in a commercial setting are described. Four Pseudomonas strains which passed the screen test are disclosed.
Abstract:
A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C-S-C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
Abstract:
The present invention relates to proteins suitable for treating or preventing an inflammatory or autoimmune condition, pharmaceutical compositions comprising same, and methods of use comprising same.
Abstract:
A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
Abstract:
Peptides derived from the N-terminal region of granulin have activity in promoting cell proliferation, migration and/or wound healing. Furthermore, an additional disulphide bond may be engineered into such peptides to improve or otherwise modify the folding of the peptide. The peptides may also be modified such as at proline residues improve the ability of the peptide to promote cell proliferation.
Abstract:
The invention relates to utilising red marine macroalgae to provide improvements in growth performance of livestock, particularly ruminant animals for red meat production, especially cattle, in pasture and feedlot farming systems. There is provided a method for improving the growth performance of a livestock animal in a farming system including: providing a red marine macroalgae to a farming system to enable consumption of the red marine macroalgae by a livestock animal in the farming system; thereby improving the growth performance of the livestock animal in the system.
Abstract:
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.